Response Biomedical Corp. develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP platform for clinical and environmental applications. The RAMP system consists of a reader and single-use disposable test cartridges. It has the potential to be adapted to more than 250 medical and non-medical tests and provide highly sensitive and reliable information in mere minutes.

RAMP clinical tests are commercially available for the early detection of heart attack and congestive heart failure. In the non-clinical market, RAMP tests are currently provided for the environmental detection of West Nile Virus and biodefense applications including the rapid on-site detection of ricin, anthrax, smallpox and botulinum toxin.

The company today announced that it has entered into an exclusive distribution agreement with Milan-based Cremascoli & Iris, s.r.l. The agreement will allow Cremascoli to distribute the full line of RAMP cardiac products in Italy. Cremascoli is a well-established company in Italy, specializing in point-of-care testing products.

The Italian market will represent a very significant opportunity for Response Biomedical. It is the second largest market in Europe, after Germany, for cardiac point-of-care testing. The Italian market for point-of-care cardiac products in expected to exceed $50 million in 2011 and is projected to grow at 5% per year through 2015. There are approximately 750 public hospitals and 400 private clinics throughout Italy.

For further information on Response Biomedical and its RAMP products, please visit the company’s website at www.responsebio.com